Compare Repligen Corporation Common Stock (RGEN) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Under Armour Inc Class A — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Under Armour Inc Class A trades at $4.79 (market cap $2.08B). The key difference: Repligen Corporation Common Stock is far larger — about 5.4× Under Armour Inc Class A's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Under Armour Inc Class A for 99 Days on average.
| RGEN | UAA | |
|---|---|---|
Market Cap | $11.14B | $2.08B |
Volume | 1,259,263 | 7,012,020 |
Sector | Health | Consumer Cyclical |
52-Week High | $194.57 | $8.14 |
52-Week Low | $102.87 | $4.17 |
Typical Hold Time | 0 Days | 99 Days |
Enterprise Value | $11.02B | $3.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Under Armour (UAA) trades at $4.79, down 2.84% on the day, amid mixed signals. The stock shows a bullish technical trend but faces fundamental headwinds with a net loss of $201.27M in 2025 and negative profit margins. Recent news highlights the company's focus on product simplification and margin recovery despite revenue weakness, with Q1 2027 earnings beating estimates but revenue falling short.
The outlook is cautious; while cost discipline supports margins, persistent revenue declines and negative cash flow pose risks. Analyst consensus is a 'Hold' with a $5.79 price target, suggesting limited upside. Investors should weigh margin improvements against top-line challenges and high short interest, which could lead to volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
